This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

CSPC Pharmaceutical Expands 2026 Share Award Pool with On-Market Buy

Tipranks - Tue Jun 9, 7:56AM CDT

Introducing TipRanks MCP for Agents

The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).

CSPC Pharmaceutical Group has disclosed that the trustee of its 2026 Restricted Share Award Scheme purchased 5.5 million shares on the market on 8 June 2026, representing about 0.05% of its issued share capital, at an average price of roughly HK$7.07 per share for a total consideration of about HK$38.9 million. Following this transaction, the trustee now holds 19.3 million shares, or 0.17% of shares outstanding, while the separate 2018 Share Award Scheme trustee holds 117 million shares, with the board signaling it will continue to exercise discretion over future on-market purchases and awards under both schemes, underscoring an ongoing commitment to equity-based incentives for selected participants.

The move increases the pool of shares available for employee and management incentives, potentially strengthening alignment between key staff and shareholders while modestly consolidating the company’s equity under trust administration. For investors, the continued use of share award schemes highlights CSPC’s reliance on stock-based compensation as a strategic tool in talent retention and performance motivation, though the current purchases represent only a small fraction of the company’s total share base.

The most recent analyst rating on (HK:1093) stock is a Buy
with a HK$13.05 price target.
To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock,
see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group focuses on the research, development and production of pharmaceutical products, and uses share award schemes to incentivize employees and align management interests with long-term shareholder value.

YTD Price Performance: -14.12%

Average Trading Volume: 95,643,013

Technical Sentiment Signal: Hold

Current Market Cap: HK$83.28B

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.